课题基金 / 基金详情

Constitution and Function of human SWI/SNF Complex : Implication in supression of carcionogenesis

Constitution and Function of human SWI/SNF Complex : Implication in supression of carcionogenesis
人类 SWI/SNF 复合物的构成和功能:抑制癌发生的意义
批准号:
14580657
负责人:
FURUKAWA Takako
金额:
$1.22万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2003

项目摘要

项目成果

FURUKAWA Takako的其他基金

相似基金

相关文献

中文摘要
翻译
我们分离了两个相关但不同的cDNA克隆,hOsa-1和hOsa-2,这是人类SWI/SNF复合物的最大组成部分。它们具有ARID (AT-rich interaction domain)和两个与果蝇Osa高度同源的区域。共免疫沉淀研究表明,这些c端同源区域对SWI/SNF的atp依赖性酶组分BRG和BRM的相互作用很重要。在培养的细胞中,hOsa刺激类固醇激素受体的转录。缺乏ARID的突变体没有刺激转录,表明该结构域在SWI/SNF功能中的重要性。我们建立了在四环素控制下以flag标记形式表达野生型或缺失ARID突变体的HeLa细胞系。用甘油梯度沉淀法分离核提取物时,在高分子量组分中发现了推定的人类SWI/SNF成分Osa、BRG、BAF155。BAF170在野生型和突变型表达细胞提取物中分布不同。BAF170与sa-2的ARID可能存在相互作用。从高分子量沉淀物中免疫纯化的野生型和突变型Osa-2复合物的银染色显示出非常相似的模式,表明ARID的存在对复合物的形成影响很小。
英文摘要
We isolated two related but distinct cDNA clones, hOsa-1 and hOsa-2, the 1argest component of human SWI/SNF complex. They had ARID (AT-rich interaction domain) and two high homology region to drosophila Osa. Co-immunoprecipitation study revealed that these C-terminal homology regions were important for the interaction with BRG and BRM, ATP-dependent enzyme componens of SWI/SNF. In cultured cells hOsa stimulated transcription by steroid hormone receptors. ARID lacking mutant did not stimulate the transcription, suggesting the importance of this domain in SWI/SNF function. We established HeLa cell lines which express either wild type or a mutant missing the ARID in Flag-tagged form under the control of tetracycline administration. Putative human SWI/SNF components, Osa, BRG, BAF155, were found in the high molecular weight fractions when the nuclear extracts were separated by glycerol gradient sedimentation. Distribution of BAF170 was different between the extracts from wild type and the mutant expressing cells. There might be some interaction between BAF170 and ARID of Osa-2. Silver staining of the complexes with wild type and the mutant Osa-2 immunopurified from the high molecular weight sedimentation fractions showed quite similar pattern, suggesting the presence of ARID has little effect on the complex formation.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
Inoue H, Furukawa T, Giannacopoulos S, Zhou S, King DS, Tanese N.: J Biol Chem. 277. 41674-41685 (2002)
Inoue H,Furukawa T,Giannacopoulos S,Zhou S,King DS,Tanese N.:生物化学杂志。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Inoue H, Furukawa T, Giannakopoulos S, et al.: "Largest subunit of the human SWI/SNF chromatin-remodeling complex promote t ranscriptional activation by steroid hormone receptors"J.Biol.Chem.. 277・44. 41467-41685 (2002)
Inoue H、Furukawa T、Giannakopoulos S 等:“人类 SWI/SNF 染色质重塑复合物的最大亚基促进类固醇激素受体的转录激活”J.Biol.Chem.. 277・44(2002 年) )
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Inoue H, Furukawa T, Giannakopoulos S, et al.: "Largest subunit of the human SWI/SNF chromatin-remodeling complex promote transcriptional activation by steroid hormon receptor"J Biol Chem. 277. 41674-41685 (2002)
Inoue H、Furukawa T、Giannakopoulos S 等人:“人类 SWI/SNF 染色质重塑复合物的最大亚基通过类固醇激素受体促进转录激活”J Biol Chem。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Basic studies for the development of a PET cancer imaging agent utilizing physical and biological properties of Zn-63
  • 批准号:
    20591488
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $2.58万
  • 财政年份:
    2008
  • 负责人:
    FURUKAWA Takako
  • 依托单位:
Basic Studies on Biochemical and Molecular Biological Diagnosis of Tumor Hypoxia by PET
国内基金
海外基金
SWI/SNF介导的表观遗传重塑与ER-α36依赖的信号编程协同调控非小细胞肺癌治疗抵抗的机制研究
  • 批准号:
    2026JJ82016
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    龚灿
  • 依托单位:
SOX11协同SWI/SNF复合物驱动染色质结构重编程调节神经祖细胞发育的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    15.0万元
  • 批准年份:
    2024
  • 负责人:
    曹春伟
  • 依托单位:
SWI/SNF复合体抑制R-Loop诱导的DNA损伤及对耐药肿瘤靶向治疗的应用
  • 批准号:
    82303636
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    王璐璐
  • 依托单位:
BRD9调控染色质重塑复合体SWI/SNF功能在三阴性乳腺癌发生发展中的作用机制研究
  • 批准号:
    32370651
  • 项目类别:
    面上项目
  • 资助金额:
    50万元
  • 批准年份:
    2023
  • 负责人:
    古莹
  • 依托单位: